Supreme Court Denies Certiorari In Generic Drug Patent Disputes

(November 9, 2015, 1:52 PM EST) -- WASHINGTON, D.C. — A March 2015 decision by the Federal Circuit U.S. Court of Appeals that reversed the dismissal of a declaratory judgment patent action will stand, thanks to the denial by the U.S. Supreme Court on Nov. 9 of two petitions for certiorari emanating from the same generic drug (Daiichi Sankyo, Inc. and Daiichi Sankyo Co., Ltd. v. Apotex, Inc.; Mylan Pharmaceuticals, Inc. v. Apotex, Inc., Nos. 15-281, 15-307, U.S. Sup.).

Active Ingredient

Respondent Apotex Inc. prevailed, turning back separate challenges to the Federal Circuit...
To view the full article, register now.